News
AI Proteins Enters into Collaborative Research Agreement with the University of Missouri on Radioligand Therapy
Boston, MA, January 8th, 2025 – AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, announced today it has entered into a Collaborative Research Agreement with the University of...
AI Proteins Appoints Founder Dr. Chris Bahl as Chief Executive Officer; Company to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week
Boston, MA, January 7th, 2025 – AI Proteins, Inc., a pioneering company utilizing artificial intelligence to design novel protein therapeutics, announces the appointment of its founder, President and Chief Scientific Officer, Dr. Chris Bahl, as Chief Executive...
AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M
Boston, MA, December 3, 2024 – AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, today announced that it has entered a Research Collaboration and Option Agreement with Bristol Myers Squibb...
AI Proteins Selected as a Winner of the Falling Walls Venture Science Start-up Competition
Company to present at Falling Walls Science Summit on November 7 BOSTON, MA, November 6, 2024 – AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, is thrilled to announce that it has been...
AI Proteins Strengthens its Leadership Team with the Addition of Biopharmaceutical Industry Veteran Michael D. Krepps as Head of Corporate Strategy
Boston, MA, June 5, 2024 – AI Proteins, Inc., a growing biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, has announced the expansion of its leadership team with the hiring of Michael D. Krepps, MS, MBA as...
AI Proteins to Attend BIO 2024; Company Provides Update on Technology Platform and Programs
Boston, MA, May 30, 2024 – AI Proteins, Inc., a growing biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, is proud to share an update on the company’s innovative research programs focused on using protein...
Vivtex and AI Proteins Enter Strategic R&D Collaboration to Develop Novel, Oral Biologic Therapies for Inflammatory Diseases
Cambridge/Boston, MA, USA – 18th January 2024 – Vivtex Corporation (“Vivtex”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, and AI Proteins, Inc., a growing biotechnology company that utilizes computational de...
AI Proteins Announces the Appointment of Dr. Robert Stein to its Scientific Advisory Board
Dr. Stein is an industry leader with over 35 years of experience in drug development BOSTON, MA, October 4, 2023 – AI Proteins, Inc. a growing biotechnology company that utilizes computational de novo protein design to create novel therapeutic miniproteins, today...
AI Proteins Strengthens Leadership with Appointment of Noah D. Beerman as Chief Executive Officer and Industry Leader Mark J. Alles as Chairman of the Board of Directors
Mr. Beerman will lead corporate and operational strategy to pioneer miniprotein therapeutics Mr. Alles brings over 30 years of pharmaceutical industry leadership to provide strategic counsel as Chairman of the Board BOSTON, MA, August 8, 2023 – AI Proteins, Inc., a...